The cancer immunotherapy revolution is here, but with thousands of new tools available preclinically and clinically there are new questions regarding how they ought to be combined to best stimulate anti-tumor immunity. Unlike other anti-cancer therapies which act directly upon tumor cells, immunotherapy acts on a complex network of the immune system that operates across large spatial and temporal scales further complicating their use. One logical tool to reprogram the immune response should be proinflammatory cytokines, but their application has been limited by delivery strategies that have been unable to allow for high concentrations of the cytokines within the tumor without toxicity. The proposed study will adapt a new nanoparticle tool that has been used to deliver one potent cytokine (IL-12) to other cytokines (IL-2, IL-15, and IL-18). Those particles will be tested as single agents for antitumor effects, immune stimulation, and toxicity and then in combination. Finally, a new generation of immunotherapy delivery vehicles will be developed that can control the release of multiple cytokines from a single nanoparticle. These tests will take place using novel models of ovarian cancer – a disease notably unresponsive to existing immunotherapies and which suffers from dismal survival rates. Overall this study will provide important new immunological insights in ovarian cancer, further the development of clinically relevant toolkits for inflammatory cytokines, and prepare a new investigator for an independent research career in immunoengineering.